In vitro Evaluation of a 20% Bioglass-Containing 3D printable PLA Composite for Bone Tissue Engineering.

Customized scaffolds for bone tissue engineering rely heavily on 3D printing technologies. While polylactic acid (PLA) is a well-established polymer in this field, its osteoinductive properties are limited. Previous studies have explored PLA composites with bioactive minerals like Bioglass (BG), but these have been restricted to BG fractions below 10% due to printability concerns. This limitation has left a gap in understanding how higher BG content affects biological activity. It was already known that BG can influence cell behavior and inflammation, but the effects of increased BG in printable composites remained unexplored. This uncertainty drove the need to evaluate a novel PLA/BG composite with higher BG content. No prior work had resolved how elevated BG fractions might affect cell adherence, metabolic activity, or inflammatory gene expression in a 3D printable format. That uncertainty motivated the current investigation into a 20% BG-containing composite.

The aim of this study was to evaluate a new 3D printable composite material containing up to 20% Bioglass (BG) for its biological activity in vitro. The specific problem addressed was the lack of data on how higher BG fractions affect scaffold biocompatibility and cell behavior. The motivation stemmed from the need to enhance bioactivity without compromising printability. The study sought to determine if increasing BG content could improve cell adherence and reduce inflammation. It also aimed to assess whether the composite could maintain printability at higher BG fractions. The researchers focused on mesenchymal stem cell (MSC) responses, including adherence, metabolic activity, and gene expression. The goal was to test whether the composite could support osteogenic potential while suppressing inflammatory responses. This work aimed to bridge the gap between material design and biological function in bone tissue engineering.

The study involved developing a 3D printable composite material combining polylactic acid (PLA) with varying percentages of Bioglass (BG). Filaments containing 5%, 10%, and 20% BG were produced for microstructure 3D printing. The researchers tested the effect of BG content on mesenchymal stem cell (MSC) activity in vitro. Cell adherence and metabolic activity were measured to assess biocompatibility. Gene expression levels for osteogenic and inflammatory markers were analyzed using molecular techniques. A whole-blood stimulation assay was performed to evaluate the material’s inflammatory potential. The experimental setup included controlled comparisons between different BG concentrations. The study focused on how increasing BG content influences biological outcomes without affecting printability. The methods combined material science with cell biology to evaluate the composite’s suitability for bone tissue engineering.

The results showed that all tested composites were biocompatible with mesenchymal stem cells (MSCs). Increasing BG content from 5% to 20% led to higher cell adherence and metabolic activity. The presence of BG had only a minor effect on osteogenic gene expression. However, it significantly suppressed the expression of inflammatory genes in MSCs. The material did not provoke a notable inflammatory response in whole-blood stimulation assays. These findings suggest that higher BG fractions can enhance bioactivity without compromising scaffold function. The 20% BG composite demonstrated the most pronounced biological effects. The results indicate that BG content can be increased while maintaining printability and biocompatibility.

The authors concluded that the 20% Bioglass (BG)-containing polylactic acid (PLA) composite is biocompatible and supports mesenchymal stem cell (MSC) activity. The study showed that increasing BG content enhances cell adherence and metabolic activity. The BG component had only a slight effect on osteogenic gene expression but significantly reduced inflammatory gene expression. The material did not provoke a strong inflammatory response in whole-blood assays. These findings suggest that higher BG fractions can improve bioactivity without affecting printability. The results support the potential of this composite for bone tissue engineering applications. The authors propose that the composite could be used to develop more bioactive scaffolds. They suggest that further in vitro and in vivo studies could explore its full potential.